DEFENCE THERAPEUTICS INC
Commented by Armin Schulz on December 12th, 2023 | 06:50 CET
BioNTech, Defence Therapeutics, Bayer - Golden times for the biotech and pharma industry?
With the arrival of winter, people are increasingly worried about illnesses such as coronavirus and influenza. The current wave of diseases and the new coronavirus variant are increasing the demand for medicines, which could positively impact the shares of pharmaceutical and biotech companies. Biotech's success in drug development for COVID-19 vaccines has allowed the industry to flourish over the past two years. But after the boom came the crash. However, the stock market always moves in cycles. The current challenges in the healthcare sector, such as the rising number of cancer cases, could, therefore, mean golden times for pharmaceutical and biotech companies, as they not only contribute to improving global health but also offer attractive returns for investors.
Read
Commented by Juliane Zielonka on December 8th, 2023 | 07:20 CET
Which stocks are leading the fight against cancer and chronic diseases? Defence Therapeutics, Merck and BioNTech
The pharmaceutical industry is facing complex developments in the fight against cancer, with Defence Therapeutics making significant progress with the successful FDA filing for its drug for the targeted treatment of tumors. The growing market opportunities in oncology until 2032 underline the potential of this breakthrough. In contrast, Merck KGaA is experiencing a severe setback with an 11% share price decline following the failure of evobrutinib for the relief of MS in late-stage clinical trials. According to analysts, this also impacts the Company's valuation. Despite promising cancer-fighting approaches, BioNTech faces uncertainties due to a reduced revenue forecast for 2023 and an 'Underweight' rating from JP Morgan. Despite these challenges, the sector remains dynamic. Find out which shares could be worthwhile in the long term here.
Read
Commented by Fabian Lorenz on November 30th, 2023 | 07:10 CET
Biotech Alert! Morphosys, Bayer, BioNTech and Defence Therapeutics
Morphosys is not for the faint-hearted. After unclear study results, the stock gave up its annual gains within a few days. Analysts are also divided on what the future holds. On December 10, the study details will be released, hopefully shedding light on the situation. Bayer shareholders are currently seeing dark clouds. The stock plummeted from EUR 40 to EUR 30 in a short time. Is the dividend now at risk, or is the entire company in jeopardy? There is a slew of positive news for Defence Therapeutics. Can the stock break out of its sideways trend? A potential partner for the Canadians could be BioNTech. The German biotech favourite is working with full coffers on cancer vaccines. However, analysts remain cautious.
Read
Commented by Stefan Feulner on November 21st, 2023 | 07:00 CET
Novo Nordisk, Defence Therapeutics, Morphosys - The biotechs are coming
The capital-intensive biotech sector was hit particularly hard when the US Federal Reserve began the massive interest rate hikes from zero to 5.5% in the first quarter of 2022. Since then, the broad-based Nasdaq Biotech Index has lost around 20% of its value. With the end of the strict monetary policy, this sector is now likely to experience a revival on the stock market. There is significant catching-up potential, especially among second-tier stocks.
Read
Commented by Armin Schulz on November 6th, 2023 | 06:45 CET
BioNTech and Bayer under pressure - Defence Therapeutics, on the other hand, with good results. Where is it worth investing?
There are currently big losers in the pharma and biotech sector among the companies that were the biggest beneficiaries of the Coronavirus Crisis. Sales at Pfizer/BioNTech are plummeting, and the entire sector is under pressure. In addition, there are patent disputes and increasing cost pressures from health insurance companies, especially in Europe. There are also high bureaucratic hurdles in the EU, meaning that more and more specialists prefer to emigrate to North America. Bayer's pharmaceuticals division is doing well, but the Company is struggling with the legal disputes surrounding the Monsanto takeover. In contrast to the first two companies mentioned, the news from Defence Therapeutics is consistently positive. We examine where it is worth getting in.
Read
Commented by André Will-Laudien on October 26th, 2023 | 08:15 CEST
Omicron or Pirola? Biotech shows doubling opportunities again! BioNTech, Pfizer, Defence Therapeutics, MorphoSys in focus
We had ticked off the Corona pandemic long ago. But if you ask your acquaintances, you may find one or two who have recently been infected with the "Pirola" variant. The official code of the virus variant is BA.2.86, and it was first discovered in Israel. The current infections are spreading rapidly across Europe and have also reached Germany. So far, the new Omicron offshoot appears less contagious than its predecessors. The new symptoms associated with "Pirola" include skin rashes, diarrhea, changes in the mouth and tongue, itchy eyes and surprisingly, sore fingers or toes. What is going on here? It is a reason to look again at BioNTech and some other biotechs. Where are the opportunities lurking?
Read
Commented by Stefan Feulner on October 16th, 2023 | 06:50 CEST
Lots of activity in the biotech sector - Novo Nordisk, Defence Therapeutics, Morphosys
Despite the rather gloomy economic outlook on the one hand and high interest rates on the other, there is significant movement in the capital-intensive biotechnology sector. After Amgen successfully concluded the acquisition of Horizon Therapeutics for USD 116.50 per share or a total volume of around USD 27.8 billion, further investments by Big Pharma in innovative and promising technologies will likely follow soon.
Read
Commented by Fabian Lorenz on October 11th, 2023 | 08:10 CEST
Attention Price Jump! Tui, Plug Power and Defence Therapeutics with News
Alarm at Tui and Deutsche Lufthansa. Both stocks are influenced by the terrorist attack in Israel this week. While the oil price is surging, aviation and tourism stocks are declining. The Tui share had already been trending weakly before. Even the leap into the profit zone could not change this. And what do analysts say? Meanwhile, Defence Therapeutics shone with positive news on a cancer therapy. As a result, the biotech share gained yesterday, offering further potential for price increases. Plug Power's share price rose by a good 7% yesterday. What is behind this?
Read
Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST
Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization
According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.
Read
Commented by André Will-Laudien on September 18th, 2023 | 06:30 CEST
Unbelievable! Hands off AI, biotech in rebound! Bayer, Defence Therapeutics, Morphosys
The big fall decline is now over. It is always a difficult time, but the so-called "Triple Witching" went relatively smoothly this time. The European Central Bank (ECB), in its first interest rate meeting after the summer break, decided to raise key rates by another quarter point to 4.00%, up from the previous 3.75% in July. At the same time, it lowered its inflation forecast for 2025 and the outlook for economic growth in the Eurozone for the years 2023 to 2025. Economic risks are increasing, but inflation remains the determining factor for interest rates. Expectations that the US Federal Reserve (FED) will announce an interest rate pause at its next meeting on Wednesday have boosted confidence. Last week's big losers were the recently favoured AI stocks Nvidia, Microsoft and C3.ai. However, the biotech sector has recently started to climb again. Where are the opportunities for investors?
Read